Physician profile
Randall K Thomas
NPI 1083607717
$125,576.23
in general payments reported to CMS, 2019-2025
13 companies · $3,445 in 2025
The $3,445 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $6,025 · 2021: $14K · 2022: $29K · 2023: $853 · 2024: $16K · 2025: $3,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Travel and Lodging: $1,827 · Food and Beverage: $1,585 · Honoraria: $525 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,750.00 |
| Travel and Lodging | $1,826.60 |
| Food and Beverage | $1,584.81 |
| Honoraria | $525.00 |
| Education | $165.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76,086.71 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $46,418.05 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Seagen INC. | $990.00 | 2022 | |
| Kala Pharmaceuticals, INC. | $700.00 | 2021 | |
| Horizon Therapeutics Plc | $690.44 | 2023 | Tepezza |
| Harrow Eye, LLC | $147.44 | 2024 | Natacyn, Verkazia, Tobradex St |
| Novartis Pharmaceuticals Corporation | $133.84 | 2022 | |
| Alcon Vision LLC | $97.01 | 2022-2025 | |
| Astellas Pharma US INC | $92.10 | 2023-2024 | Padcev |
| Tarsus Pharmaceuticals, INC. | $87.00 | 2025 | Xdemvy |
| Astellas Pharma Global Development | $69.14 | 2024-2025 | Izervay |
| Thea Pharma INC. | $38.32 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $26.18 | 2025 | Istent Infinite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.